NovoBiotics Pharmaceuticals

NovoBiotic Pharmaceuticals is a privately held biotechnology company based in Woburn, Massachusetts, specializing in the discovery of novel antibiotics from previously "unculturable" microorganisms. The company utilizes its proprietary iChip (isolation chip) technology to culture soil and marine bacteria in their natural environments, providing access to a vast and untapped source of natural product diversity. Its lead candidate, Teixobactin, is a first-in-class antibiotic that targets essential cell wall precursors (Lipid II and Lipid III) and has shown no detectable resistance in preclinical studies. Other notable programs include Clovibactin, another resistance-evading antibiotic, and Lassomycin, which targets Mycobacterium tuberculosis. NovoBiotic's research is supported by significant grants from the NIH, NIAID, and the Bill & Melinda Gates Foundation.